YueXiangYue Health Submits IPO Prospectus in August 2024

On August 6, Cloudbreak Pharma Inc. ("Cloudbreak," formerly known as "Boyun Bio") and Santen Pharmaceutical Co., Ltd. ("Santen Pharmaceutical"), a specialized ophthalmic company, announced the signing of a licensing agreement. Cloudbreak will license its multi-kinase inhibitor CBT-001, currently under development for the treatment of pterygium, to Santen Pharmaceutical for the Southeast Asian region, including Japan, South Korea, Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia (hereinafter referred to as the "Region"). Under the terms of the agreement, Cloudbreak grants Santen Pharmaceutical the rights to develop, manufacture, and commercialize the CBT-001 drug within this Region.

According to the agreement, Bokang Shi Yun will receive an upfront payment and milestone payments totaling up to 91 million US dollars. In addition, Bokang Shi Yun will also receive a double-digit percentage of the product's future net sales as royalties.

On August 28, the TrueSky® Support Catheter independently developed by Shenzhen Northcore Life Technology Co., Ltd. officially received the Class III Medical Device Registration Certificate issued by the National Medical Products Administration (NMPA). As a domestically produced high-support shapable peripheral support catheter, the product features excellent shapeability, support, and deliverability, and is used in peripheral vascular interventional procedures.

On August 15, TrueRail™ Support Catheter, independently developed by NorthX Life, officially obtained the Class III medical device registration certificate issued by the National Medical Products Administration (NMPA). As a domestically produced multi-imaging measurable peripheral support catheter, this product enables operators to more accurately measure blood vessels and access lesion areas, offering excellent measurability, support, and deliverability.

In August, the Guangzhou Association of Science and Technology Innovation Enterprises officially announced the list of selected products for the 2024 Guangzhou Innovative Products Catalog (First Batch). Guangzhou Maijing Gene Medicine Science and Technology Co., Ltd. successfully made it to this prestigious list with its two outstanding PCR companion diagnostic products for lung cancer and colorectal cancer, marking a high level of recognition for Maijing Gene in both technological innovation and market application.

In August, the NGS multi-gene companion diagnostic kit (trade name: Jingjianxin™) independently developed by Guangzhou Maijing Gene Medicine Science and Technology Co., Ltd. was approved for a Class III medical device registration certificate (registration number: Guo Xie Zhu Zhun 20243401417) by the National Medical Products Administration (NMPA). This is the third Class III medical device registration certificate obtained by Maijing Gene, as well as the second one in 2024, further demonstrating Maijing Gene's leading position in the field of molecular diagnostics for tumors. It also marks another milestone in Maijing Gene’s development strategy of "strong R&D focus and emphasis on registration."

In August, Professor Zhao Hongyun and Professor Zhang Li from the Sun Yat-sen University Cancer Center, in collaboration with Guangzhou Maijing Gene Medicine Science and Technology Co., Ltd., used an NGS detection panel to explore for the first time the impact of TP53 mutations causing α-helix region alterations on clinical outcomes. Dr. Li Mengzhen from Maijing Gene provided technical consultation and analysis support for this project.

On August 29, Biostar, a biomedical company that relies on a synthetic biology R&D platform to focus on developing proprietary anti-cancer drugs, announced through its U.S. subsidiary, Biostar Pharma, Inc., that the U.S. Phase I clinical trial (NCT05681000) of its key pipeline product, UTD2 (Oral Capsule of Utidelone), for patients with advanced solid tumors, has completed the enrollment of all patients.

On August 7, Lingyi (Hangzhou) Biotechnology Co., Ltd. announced that its self-developed gene therapy drug LY-M003 injection received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Wilson’s disease (WD). This follows the FDA Rare Pediatric Disease Designation (RPDD) granted in mid-July, further recognizing the potential clinical value of LY-M003 injection.

In August, the article "Proteomic landscape of epithelial ovarian cancer" published in Nature Communications by Westlake Omics in collaboration with Professor Tian-Nan Guo's team from the School of Medicine at Westlake University, Zhi-Guo Zheng/Jian-Qing Zhu from Zhejiang Cancer Hospital, and Professor Yue-Jin Hua's team from Zhejiang University, was selected as a featured article by the journal and included in the Cancer category of the Editors’ Highlights section.

On August 15, Quanxin Bio-B (02509.HK) announced that for the six months ended June 30, 2024, the group's revenue reached RMB 44.919 million, derived from licensing fees and research and development service fees related to the external licensing transactions of QX008N and QX004N, reflecting the group’s strong R&D capabilities.

On the evening of August 28, the semi-annual report released by APL Micromatrix (688176) for 2024 showed that the company demonstrated a forward-looking momentum: the launch process of its key product, APL-1702, is proceeding in an orderly manner; its commercial "self-sustaining" capability continues to strengthen; and its innovative pipeline is actively advancing. To date, the company's main product pipeline includes 13 products and 18 ongoing research projects. At the end of the reporting period, the company held approximately RMB 2.024 billion in cash and cash equivalents as well as trading financial assets, with ample financial reserves.

On August 7, Cat's Eye Biotechnology (Suzhou) Co., Ltd. and Weiguang Gene (Suzhou) Co., Ltd. signed a strategic cooperation agreement, reaching a cooperation intention on advanced gene editing tools for commercial production services. Attending the signing ceremony were Dr. Wang Xiao, co-founder and CEO of Cat's Eye Biotechnology, Dr. Park Hee-jun, Vice President of Technology, and Ms. Xie Bohua, Vice President of Business Management; Dr. Hu Yang, CEO of Weiguang Gene, Mr. Tan Yaozu, Director of Business, and Ms. Liu Wei, Financial Director.

The Jiangsu Provincial Department of Industry and Information Technology announced the 2024 list of intelligent manufacturing workshops in Jiangsu Province. After procedures such as enterprise application, formal review, expert evaluation, and on-site inspection, Cytiva Biologics was officially selected as a representative of intelligent manufacturing in the biopharmaceutical field for the 2024 Jiangsu Province Intelligent Manufacturing Workshop.

In August, the National Medical Products Administration conducted a regular on-site inspection lasting one week on the implementation of the "Good Laboratory Practice for Nonclinical Laboratory Studies" (hereinafter referred to as GLP) at the Wuhan branch of Hubei Tianqin Biotechnology Co., Ltd. (hereinafter referred to as "Tianqin Biotech Wuhan Branch"), and the results were all successfully passed.

On August 27, Chongqing Zhirong Jintai Biopharmaceutical Co., Ltd. ("Zhirong Jintai") received the "Drug Registration Certificate" issued by the National Medical Products Administration (NMPA) for its self-developed Class 1 new drug, Selicibart Injection (brand name: Jinlix®), officially approving it for market launch. Hubei Tianqin Xinsaint Biotechnology Co., Ltd. ("Tianqin Xinsaint"), a subsidiary of Tianqin Biotech, provided partial preclinical safety evaluation test services for this project, fully supporting the product’s successful approval and market entry.

JH013 Injection, a Class I new drug jointly submitted by Bio-Thera Solutions and Ambitex Pharma, has been granted the clinical trial approval (IND) by the Center for Drug Evaluation of the National Medical Products Administration, allowing it to proceed with clinical trials. Wuhan Branch of Tianqin Biotechnology, commissioned by Bio-Thera Solutions/Ambitex Pharma, provided a full set of non-clinical toxicology, pharmacokinetics, and tissue cross-reactivity testing services for the project, contributing to its successful IND approval and advancement into the clinical trial phase.

Recently, the People's Health Publishing House has successively released the tenth edition of the national five-year undergraduate clinical medicine program planning materials for higher education institutions in China. Chiglitazar Sodium, an original new drug independently developed by Chipscreen Biosciences for treating type 2 diabetes, has been included in the seventh section on Endocrine and Metabolic Diseases in the new edition of *Internal Medicine*.

MicroCore Biotech and its wholly-owned subsidiary Chengdu MicroCore Pharmaceuticals Co., Ltd. have received the "Acceptance Notice" for the clinical trial registration of domestically produced drugs issued by the National Medical Products Administration (NMPA). The Phase III clinical trial application for Xiaoluo Ni combined with PD-(L)1 monoclonal antibody and chemotherapy as first-line treatment for extensive-stage small cell lung cancer has been accepted.

On August 15, Chipscreen Biosciences released its semi-annual report for 2024. In the first half of the year, the company achieved operating revenue of 302 million yuan, representing a year-on-year increase of 25.06%; net profit attributable to shareholders was a loss of 41.0064 million yuan, representing a year-on-year decrease of 126.34%, turning from profit to loss compared with the same period last year. The semi-annual report showed that the growth in operating revenue was mainly due to a 11.74% year-on-year increase in the sales volume of Chidamide, with revenue increasing by 4.15% year-on-year (after a 6% price reduction under the medical insurance scheme); the sales volume of Ciglitazone increased by 396.15% year-on-year, with revenue increasing by 632.48% year-on-year.

On August 21-22, 2024, the 18th China Fund Partners Summit, hosted by Zero2IPO and Investment界, was held in Shanghai. Yi Feng Capital's CEO Zhu Pai was invited to participate in the Impact Dialogue titled "Building a New Ecosystem for Industrial Investment" and served as the moderator for the roundtable discussion. The event featured engaging discussions on new changes in the industry ecosystem, how institutions, enterprises, and the government can collaborate for mutual benefit, and the opportunities and challenges presented by the trend of expanding overseas.

According to the National Health Commission of China, the proportion of people with high uric acid in China is increasing year by year and is showing a trend of becoming younger. A large number of young people, especially males, have been found to have high uric acid during physical examinations. High uric acid has become so common that it can be mentioned alongside high blood lipids, high blood pressure, and high blood sugar, collectively known as the "four highs."

Excessive Exercise Lowers Immunity: A Fact Contrary to Common Belief but a "Common Knowledge" in Sports CirclesA set of data from overseas shows that 50%-70% of athletes experience upper respiratory tract infection (URTI) symptoms—typically discomfort in the nose and throat—within two weeks after participating in major competitions, especially exhaustive aerobic endurance events. Long-distance runners and those undergoing high-intensity training have an incidence of URTI that is 2-4 times higher than those with low-intensity training.